Skip to content
Recall Observatory FDA recall evidence

Drug product

JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA

D-0468-2023

March 09, 2023

Class II

Product summary

Firm
Boehringer Ingelheim Pharmaceuticals, Inc.
Event
Event 91879
Status
Terminated
Classification
Class II
Quantity
69,375 bottles
Official record key
drug-enforcement:D-0468-2023

Official wording

Reason: Labeling: Label Mix-up

Code information: Lot #: a) and b) E61835, exp. date JUN 2025

Distribution pattern: Product was distributed nationwide within the United States and PR

Derived failure modes

  • Labeling or packaging

    reason.labeling_packaging · v1.0.0

    Labeling: Label Mix-up